Roger Perlmutter, 2016 Institute for Systems Biology via Youtube
June 9, 2020 04:45 PM EDTUpdated June 9, 10:05 PM
R&D

King Keytru­da floun­ders in an­oth­er piv­otal can­cer study. And that may spur doubts about Mer­ck­'s stay­ing pow­er

John Carroll

Editor & Founder

The king of the PD-(L)1 class is see­ing a few cracks start to ap­pear in the crown.

Mer­ck re­port­ed Tues­day evening that its Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

Ex­clu­sive: BigHat inks Lil­ly deal for AI-boost­ed an­ti­bod­ies, ex­tends Se­ries B

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times